156 related articles for article (PubMed ID: 23116281)
1. Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease.
Godinho BM; Ogier JR; Darcy R; O'Driscoll CM; Cryan JF
Mol Pharm; 2013 Feb; 10(2):640-9. PubMed ID: 23116281
[TBL] [Abstract][Full Text] [Related]
2. Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system.
Godinho BM; McCarthy DJ; Torres-Fuentes C; Beltrán CJ; McCarthy J; Quinlan A; Ogier JR; Darcy R; O'Driscoll CM; Cryan JF
Biomaterials; 2014 Jan; 35(1):489-99. PubMed ID: 24138827
[TBL] [Abstract][Full Text] [Related]
3. Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model.
Mendonça MCP; Cronin MF; Cryan JF; O'Driscoll CM
Eur J Pharm Biopharm; 2021 Dec; 169():309-318. PubMed ID: 34793942
[TBL] [Abstract][Full Text] [Related]
4. PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability.
Godinho BM; Ogier JR; Quinlan A; Darcy R; Griffin BT; Cryan JF; O'Driscoll CM
Int J Pharm; 2014 Oct; 473(1-2):105-12. PubMed ID: 24992319
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: effect of reversing primary and secondary face modifications.
O'Mahony AM; Doyle D; Darcy R; Cryan JF; O'Driscoll CM
Eur J Pharm Sci; 2012 Dec; 47(5):896-903. PubMed ID: 23022516
[TBL] [Abstract][Full Text] [Related]
6. Nonviral siRNA delivery for gene silencing in neurodegenerative diseases.
Prakash S; Malhotra M; Rengaswamy V
Methods Mol Biol; 2010; 623():211-29. PubMed ID: 20217554
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.
Zhang L; Wu T; Shan Y; Li G; Ni X; Chen X; Hu X; Lin L; Li Y; Guan Y; Gao J; Chen D; Zhang Y; Pei Z; Chen X
Brain; 2021 Dec; 144(11):3421-3435. PubMed ID: 34918046
[TBL] [Abstract][Full Text] [Related]
8. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.
Guo J; Ogier JR; Desgranges S; Darcy R; O'Driscoll C
Biomaterials; 2012 Nov; 33(31):7775-84. PubMed ID: 22828585
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
11. Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery.
O'Mahony AM; Godinho BM; Ogier J; Devocelle M; Darcy R; Cryan JF; O'Driscoll CM
ACS Chem Neurosci; 2012 Oct; 3(10):744-52. PubMed ID: 23077718
[TBL] [Abstract][Full Text] [Related]
12. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
13. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
14. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology.
Klejbor I; Stachowiak EK; Bharali DJ; Roy I; Spodnik I; Morys J; Bergey EJ; Prasad PN; Stachowiak MK
J Neurosci Methods; 2007 Sep; 165(2):230-43. PubMed ID: 17655935
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for Huntington's disease.
Ramaswamy S; Kordower JH
Neurobiol Dis; 2012 Nov; 48(2):243-54. PubMed ID: 22222669
[TBL] [Abstract][Full Text] [Related]
16. Potential use of lactosylated dendrimer (G3)/α-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy.
Hayashi Y; Mori Y; Yamashita S; Motoyama K; Higashi T; Jono H; Ando Y; Arima H
Mol Pharm; 2012 Jun; 9(6):1645-53. PubMed ID: 22510029
[TBL] [Abstract][Full Text] [Related]
17. Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles.
Wong Y; Markham K; Xu ZP; Chen M; Max Lu GQ; Bartlett PF; Cooper HM
Biomaterials; 2010 Nov; 31(33):8770-9. PubMed ID: 20709387
[TBL] [Abstract][Full Text] [Related]
18. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
19. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.
Mao CQ; Du JZ; Sun TM; Yao YD; Zhang PZ; Song EW; Wang J
Biomaterials; 2011 Apr; 32(11):3124-33. PubMed ID: 21277018
[TBL] [Abstract][Full Text] [Related]
20. Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington's disease gene expression following intranasal administration.
Sava V; Fihurka O; Khvorova A; Sanchez-Ramos J
Nanomedicine; 2020 Feb; 24():102119. PubMed ID: 31666200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
